Bristol-Myers Squibb – media

Bristol-Myers Squibb’s Combo Drug gets FDA Approval

Bristol-Myers Squibb’s recent immunotherapy combo won FDA approval for patients with a rare colon cancer. The combinational medicine was formulated between an older medicine named Yervoy and a new cancer-fighter Opdivo. This combo drug focuses on repairing the mismatch gene.
- Source: FiercePharma
- 4,415
- July 13, 2018
Bristol-Myers Squibb cancer colorectal cancer New Approvals
Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy

Factor XIa inhibitor moving into Phase 2 Trials for Secondary Stroke Prevention Bristol-Myers Squibb to receive upfront payment and companies to share development and commercialization costs, and global profits
- Source: news.bms
- 620
- April 23, 2018
Bristol-Myers Squibb Cardiovascular Therapy Janssen
Bristol-Myers Squibb and Harvard Announce New Fibrosis Research Collaboration

Bristol-Myers Squibb Company and the Harvard Fibrosis Network of the Harvard Stem Cell Institute today announce a research collaboration to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart. The Harvard Fibrosis Network brings together researchers across the schools and affiliated hospitals of Harvard University.
- Source: news.bms
- 608
- April 13, 2018
Bristol-Myers Squibb fibrotic diseases
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer

Application based on results from Phase 2 CheckMate -142 study
- Source: investors.bms
- 620
- April 11, 2018
Bristol-Myers Squibb FDA New Approvals Opdivo
Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone

Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, announced that a development milestone for cabiralizumab has been achieved, triggering a $25 million payment from Bristol-Myers Squibb Company (BMS) (BMY) under the license and collaboration agreement between the companies established in 2015. The milestone was triggered by initiation of a multi-arm Phase 2 clinical trial (NCT03336216), sponsored by Bristol-Myers Squibb Company, evaluating cabiralizumab and Opdivo® (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer. “Effective treatment for patients with pancreatic cancer remains a significant unmet need and is a cancer for which existing immunotherapies have not been successful to date,” said Helen Collins, M.D., Senior Vice President and Chief Medical Officer of Five Prime. “We are encouraged by the preliminary data presented at SITC 2017 and are pleased to see this trial underway.” The Phase 2 trial is expected to enroll approximately 160 ...
- Source: finance.yahoo
- 564
- January 31, 2018
Bristol-Myers Squibb cabiralizumab Opdivo

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.